

## CLAIMS

What is claimed is:

1. An isolated antibody or an antigen-binding fragment thereof, comprising:
  - (a) a heavy chain variable domain (VH) comprising:
    - i. complementarity a heavy chain determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:27-39;
    - ii. a heavy chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:40-52; and
    - iii. a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:53-65, respectively; and
  - (b) a light chain variable domain (VL) comprising:
    - i. a light chain CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:66-78;
    - ii. a light chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:79-91; and
    - iii. a light chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:92-104, respectively;

wherein the antibody or antigen-binding fragment thereof is capable of specifically binding to a TIGIT, preferably a human TIGIT, or pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof or a second isolated antibody or antigen-binding fragment thereof capable of specifically binding to TIGIT competitively with the isolated antibody or antigen-binding fragment thereof, and a pharmaceutically acceptable carrier for use in treating a TIGIT related disease in a subject in need thereof, wherein the subject is human.